MedTrace Logo

The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients

NCT00119769 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2008-08-27

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of low-dose human growth hormone therapy on immune status and fat morphology.

Conditions

  • HIV Infections
  • Lipodystrophy

Interventions

DRUG

Placebo

Placebo, 0.7 mg/day injected subcutaneously

DRUG

Genotropin (human recombinant Growth hormone)

Genotropin, 0.7 mg/day injected subcutaneously

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Hvidovre University Hospital

    lead OTHER

Principal Investigators

  • Birgitte R Hansen, MD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2007-05-31
Completion
2008-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00119769 on ClinicalTrials.gov